Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) (PrE0905)

The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for a particular change in AML of their leukemia cells (called a mutation) in a gene called FLT3.
Zayda Benavidez at zbenavidez@pennstatehealth.psu.edu or 717-531-8678
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03836209
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
AML with FLT3 mutation status (includes signal ratio)
Verified confirmation that blasts are myeloid
Verified NPM1 mutation status
Must have an ECOG performance status of 0-3
Must have adequate organ function as measured by criteria
Exclusion Criteria:
May not have M3 AML
May not have known active Central Nervous System (CNS) leukemia
Not a woman of childbearing potential (WOCBP) or who agrees to follow the contraceptive guidance
May not have a history of Long QT Syndrome
May not have evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or congestive heart failure
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA